Eisbach develops novel medicines that target chromatin regulatory mechanisms essential to tumors.
Our novel targets and best-in-class drug discovery allow us to develop a pipeline of impactful medicines.
A Bold Approach
A tumors genome constantly evolves. This makes tumors incredibly difficult to target.
We identified the engines that drive all genome rearrangements in tumors.
Our unique screening and cellular platforms are generating first-in-class inhibitors that allow us to directly target the key vulnerability present in genetically-defined tumors.
Our Clinical Goal
Specific tumors have specific biological requirements.
Our targets are essential in these genetically-defined tumors.
Our inhibitors thus target tumor cells in a highly specific and personalised manner.
By leveraging epigenetic mechanisms, we can now address unmet clinical needs.
We strive for better cures
Now is the time to leverage
the power of genomics
to develop the right drugs
for the right patients.
Tumors harbor genetic fingerprints that reveal their Achilles heel
Physiological assays identify drugs that hit this weak spot
for defined patient populations
Our Management Team
In our team we combine proprietary scientific knowledge of our target enzymes, in-depth understanding of drug discovery and broad executive experience
Adrian Schomburg, PhD, is a drug discovery expert with over 10 years of experience in pharma and biotech. He moved projects successfully through drug discovery - from target identification to the delivery of preclinical and development candidates. In his former roles at Pfizer and Proteros, he kick-started collaborative R&D projects in epigenetics with big pharma.
Prof. Andreas Ladurner, PhD, is a globally recognized expert in chromatin biology and metabolism. His pioneering discoveries include the discovery of bromodomain and macrodomain function, including the allosteric regulation of key epigenetic enzymes. He is Chair and Full Professor of Physiological Chemistry at the LMU in Munich.
News and Press Coverage
BMBF announced 8 million EUR funding for COVID-19 antiviral clinical development
Eisbach Bio receives government grant to progress COVID-19 antiviral through Phase I/II clinical development
Collaboration with the Core Facility Animal Models BMC to test SARS-CoV-2 antivirals
Coaxing cancer cells to commit suicide - Recent collaboration with the LMU
Video Interview for Reuters TV
Article in ZDF-Heute
Interview for Süddeutsche Zeitung
Eisbach joins worldwide efforts to combat COVID-19
Eisbach presented at BIOTECH SHOWCASE™ 2020 in San Francisco
1st Prize Winner Startup Slam at BioEurope 2019
1st Prize Rising Stars Award at the BioEntrepreneurship Summit
Winner of the EIT Health Germany Headstart Awards 2019
BioM press release on Eisbach Bio
Eisbach is now eligible for the INVEST funding programme of the BMWi.
Moved into incubator lab space at the Ludwig-Maximilians-Universität Munich
1st Prize Winner of the BioM Bio Entrepreneur Boot Camp 2018
We are supported by:
Find us at the office
Trailor- Verkamp street no. 63, 81415 Zagreb, Croatia
Give us a ring
+38 695 645 231
Mon - Fri, 8:00-22:00